SEC Form 4 · accession 0001140361-18-045056
Organogenesis Holdings Inc. · ORGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hakan Bjorklund
Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 9:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001661181
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B Ordinary SharesF2,F1 | — | Dec 10, 2018 | D | 243,896 | D | — | — | Class A Ordinary Shares | 243,896 | 69,571 | D |
Explanation of responses
- F1Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.
- F2243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.
Remarks
In connection with the closing of the Business Combination, the Issuer's name was changed to Organogenesis Holdings Inc.